Trial · NCT00972777
Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis
NCT00972777, Phase 2, Phase 3, Completed, Bausch & Lomb Incorporated; results first posted 2012-03-29
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis. Trials, record NCT00972777. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00972777
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis
- NCT number
- NCT00972777
- Status
- Completed
- Phases
- Phase 2, Phase 3
- Enrollment
- 474 participants, actual
- Lead sponsor
- Bausch & Lomb Incorporated
- Conditions
- Bacterial Conjunctivitis
- Interventions
- Besifloxacin, Vehicle (Placebo)
- First posted
- 2009-09-09
- Last updated
- 2012-03-29
- Results first posted
- 2012-03-29
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Clinical Resolution | Visit 2 | The absence of both conjunctival discharge and bulbar conjunctival injection. |
| Primary | Microbial Eradication | Visit 2 | The absence of ocular bacteria that were present at or above pathogenic threshold levels at baseline. |
| Secondary | Clinical Resolution | Visit 3 | The absence of both conjunctival discharge and bulbar conjunctival injection. |
| Secondary | Microbial Eradication | Visit 3 | The absence of ocular bacteria that were present at or above pathogenic threshold levels at baseline. |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Clinical Resolution | Visit 2 | Clinical Resolution at Visit 2, (LOCF), mITT Population. | eyes | NUMBER |
| PRIMARY | Microbial Eradication | Visit 2 | Microbial Eradication at Visit 2, (LOCF), mITT Population. | eyes | NUMBER |
| SECONDARY | Clinical Resolution | Visit 3 | Clinical Resolution at Visit 3, (LOCF) mITT Population. | eyes | NUMBER |
| SECONDARY | Microbial Eradication | Visit 3 | Microbial Eradication at Visit 3, (LOCF), mITT Population. | eyes | NUMBER |
Source ClinicalTrials.gov
Results by group8
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Clinical Resolution | Besifloxacin | 89 | eyes | ||
| Clinical Resolution | Vehicle | 62 | eyes | ||
| Microbial Eradication | Besifloxacin | 115 | eyes | ||
| Microbial Eradication | Vehicle | 77 | eyes | ||
| Clinical Resolution | Besifloxacin | 103 | eyes | ||
| Clinical Resolution | Vehicle | 94 | eyes | ||
| Microbial Eradication | Besifloxacin | 115 | eyes | ||
| Microbial Eradication | Vehicle | 91 | eyes |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Besifloxacin | 231 | |
| Overall Study | STARTED | Vehicle | 243 | |
| Overall Study | COMPLETED | Besifloxacin | 217 | |
| Overall Study | COMPLETED | Vehicle | 229 | |
| Overall Study | NOT COMPLETED | Besifloxacin | 14 | |
| Overall Study | NOT COMPLETED | Vehicle | 14 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Besifloxacin | ||
| Total, all-cause mortality | Vehicle | ||
| Total, other adverse events | Besifloxacin | 0 | 228 |
| Total, other adverse events | Vehicle | 0 | 236 |
| Total, serious adverse events | Besifloxacin | 0 | 228 |
| Total, serious adverse events | Vehicle | 0 | 236 |
Source ClinicalTrials.gov
Papers3
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons1
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison |
|---|
| Besifloxacin vs Vehicle: serious adverse events |
Source Trial comparisons
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00972777
GET https://conductscience.org/api/trials/v1/NCT00972777/registered